Germany's IQWiG angers Novo Nordisk with Tresiba rejection
This article was originally published in Scrip
Executive Summary
Germany's IQWiG, the country's health technology appraisal institute, has rejected Novo Nordisk's Tresiba (insulin degludec) for "formal reasons," claiming it was unable to reach a conclusion on the drug's additional benefit. Novo Nordisk has objected to the assessment's outcome.